• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor

byDayton McMillan
September 4, 2019
in Chronic Disease, Oncology, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Approximately a quarter of multiple myeloma patients that had refractory disease despite treatment with a proteasome inhibitor, immunomodulatory agent, and daratumumab experienced treatment response with selinexor and dexamethasone.

2. Thrombocytopenia was a common adverse event in patients.

Evidence Rating Level: 2 (Good)  

Study Rundown: Relapse is common for multiple myeloma patients despite the use of therapies than span a number of treatment mechanisms. Triple class refractory patients, those treated with a proteasome inhibitor, immunomodulatory agent, and monoclonal antibodies previously, are becoming more common and these patients have poor survival outcomes. Exportin 1 is a nuclear exporter of various pro-oncogenic materials and is overexpressed in myeloma patients. Selinexor is a recently approved oral inhibitor of the exportin 1 nuclear exporter. A previous dose finding study showed selinexor with dexamethasone in triple-refractory multiple myeloma patients resulted in response for a portion of the patients. The Selinexor Treatment of Refractory Myeloma (STORM) part 2 study further evaluates treatment of triple refractory patients with selinexor and dexamethasone. The primary outcome of partial response or better (overall response) occurred in 26% of patients. Median overall survival in these patients was 8.6 months. Thrombocytopenia occurred in the majority of patients.

This study suggests efficacy of a novel treatment in a treatment resistant multiple myeloma population with poor survival outcomes. Strengths of the study include evaluation of multiple response outcomes while it is limited by the very high rate of treatment discontinuation.

Click to read the study in NEJM

Relevant Reading: A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia

RELATED REPORTS

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

Iberdomide elicits SRI-4 response in patients with systemic lupus erythematosus

In-Depth [prospective cohort]: This phase 2b, open-label, single-arm trial enrolled patients from 2015 to 2018. Eligible patients had multiple myeloma, were reasonably functional according to a performance status score, had adequate liver/kidney/hematopoietic function, and had disease refractory to a proteasome inhibitor, immunomodulatory agent, and monoclonal antibody therapy. All patients (n=122) received 80mg of selinexor and 20mg of dexamethasone biweekly in 4-week cycles until death, disease progression, or discontinuation. Patients were provided with antiemetic medications. The primary endpoint was overall response, defined as a 50% or greater reduction in serum myeloma protein. Overall response was observed in 26% of patients (95% confidence interval [CI], 19 to 35) and 2 patients had a complete response. Discontinuation of treatment due to any cause occurred in 96% of patients, while 18% of patients discontinued treatment due to an adverse event considered related to treatment. Median time to a clinical response was 4.1 weeks. Median progression free survival was 3.7 months (95% CI, 3.0 to 5.3) and median overall survival was 8.6 months (95% CI, 6.2 to 11.3). Thrombocytopenia and occurred in 73% of patients, respectfully. Grade 3 or 4 thrombocytopenia occurred in 59% of patients. Adverse events that resulted in dose modification or interruption occurred in 80% of patients. Serious adverse events occurred in 63% of patients.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: dexamethasoneexportinimmunomodulatorsmonoclonal antibodymultiple myelomaproteasome inhibitorselinexor
Previous Post

Quick Take: Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL)

Next Post

#VisualAbstract: Immediate Transfusion in African Children with Uncomplicated Severe Anemia

RelatedReports

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients
StudyGraphics

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

June 30, 2022
#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
StudyGraphics

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

May 19, 2022
Multidrug induction therapy increases remission from lupus nephritis
Chronic Disease

Iberdomide elicits SRI-4 response in patients with systemic lupus erythematosus

March 21, 2022
#VisualAbstract: Casirivimab and imdevimab reduced mortality in seronegative patients with COVID-19
StudyGraphics

#VisualAbstract: Casirivimab and imdevimab reduced mortality in seronegative patients with COVID-19

March 3, 2022
Next Post
#VisualAbstract: Immediate Transfusion in African Children with Uncomplicated Severe Anemia

#VisualAbstract: Immediate Transfusion in African Children with Uncomplicated Severe Anemia

#VisualAbstract: Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

#VisualAbstract: Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Parents often unaware of adolescents’ suicidal thoughts

Quick Take: Association of Childhood-Onset Inflammatory Bowel Disease With Risk of Psychiatric Disorders and Suicide Attempt

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Hybrid immunity protects against infection with omicron variant of COVID-19
  • #VisualAbstract: Tirzepatide Once Weekly for the Treatment of Obesity
  • Wellness Check: Sleep
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.